VBLT

The latest analyst coverage could presage a bad day for Vascular Biogenics Ltd. (NASDAQ:VBLT), with the analysts...

This article will reflect on the compensation paid to Dror Harats who has served as CEO of Vascular Biogenics Ltd...

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and 28.67%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Vascular Biogenics (NASDAQ:VBLT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.13) by 7.69 percent. This is a 14.29 percent increase over losses of $(0.14) per share from

VBL Therapeutics (VBLT): Q3 GAAP EPS of -$0.12 beats by $0.01.Revenue of $0.19M (+137.5% Y/Y) misses by $0.01M.Press Release

NEW YORK, NY / ACCESSWIRE / November 16, 2020 / Vascular Biogenics Ltd.

Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market.

Vascular Biogenics (NASDAQ: VBLT) announces its next round of earnings this Monday, November 16. Here is Benzinga's everything-that-matters guide for this Monday's Q3 earnings announcement.Net Income, Earnings, And Earnings Per Share Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.Earnings And Revenue Sell-side analysts are expecting Vascular Biogenics's loss per share to be near $0.13 on sales of $170.00 thousand. In the same quarter last year, Vascular Biogenics announced EPS of $0.14 on revenue of $79.00 thousand.What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter? Wall Street analysts who study this company will publish analyst estimates of revenue and EPS. The averages of all analyst EPS and revenue estimates are called the "consensus estimates"; these consensus estimates can have a significant effect on a company's performance during an earnings release. When a company posts earnings or revenue above or below a consensus estimate, it has posted an "earnings surprise", which can really move a stock depending on the difference between actual and estimated values.View more earnings on VBLTIf the company were to report earnings in line when it publishes results Monday, quarterly profit would be up 7.14%. Revenue would be up 115.19% from the same quarter last year. Vascular Biogenics's reported EPS has stacked up against analyst estimates in the past like this:Quarter Q2 2020 Q1 2020 Q4 2020 Q3 2019 EPS Estimate -0.14 -0.17 -0.13 -0.14 EPS Actual -0.14 -0.15 -0.16 -0.14 Revenue Estimate 150.00 K 160.00 K 110.00 K 120.00 K Revenue Actual 158.00 K 366.00 K 126.00 K 79.00 K Stock Performance Shares of Vascular Biogenics were trading at $1.12 as of November 12. Over the last 52-week period, shares are down 2.99%. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release.Do not be surprised to see the stock move on comments made during its conference call. Vascular Biogenics is scheduled to hold the call at 08:30:00 ET and can be accessed here.See more from Benzinga * Click here for options trades from Benzinga * Sogou Earnings Preview * Earnings Preview: LiveXLive Media(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.